Fosun International Ltd
(OTCPK:FOSUF)
$
0.67
(0%)
Market Cap: 5.16 Bil
Enterprise Value: 32.70 Bil
PE Ratio: 0
PB Ratio: 0.37
GF Score: 36/100 
Half Year 2026 Fosun International Ltd Earnings Call Transcript
Aug 28, 2026 / 02:00AM GMT
Release Date Price:
$0.65666
Key Points
Positve
- Fosun International Ltd (FOSUF) reported a 160.3% year-on-year increase in net profit attributable to owners of the parent, reaching RMB1.72 billion, driven by higher industrial operating profit and lower headquarters finance costs.
- The company's industrial operating profit grew by 17% year-on-year to RMB3.69 billion, with strong performance across all four business segments, showcasing diversification and risk resilience.
- Fosun International Ltd (FOSUF) continued to deleverage, reducing group-level interest-bearing debt from RMB89.9 billion at the end of 2025 to RMB85.4 billion by June 2026, and is committed to a mid-term target of RMB60 billion.
- The company's insurance segment showed robust growth, with total premiums reaching RMB52.7 billion, and Fidelidade maintaining a 30% market share in Portugal, while Fosin Life Insurance saw a 52.2% increase in total premiums.
- Fosun International Ltd (FOSUF) is advancing its globalization strategy, with overseas revenue accounting for 56% of total revenue, and core businesses like Fosun Pharma and Hainan Mining expanding their global footprint, including new markets in the US, EU, and Africa.
- The company is committed to shareholder returns, targeting a payout ratio of 35% and expecting dividends for fiscal year 2026 to be no less than HK$1.5 billion, with major shareholders planning to purchase up to HK$500 million in shares.
- Fosun International Ltd (FOSUF) is actively unlocking value through asset spin-offs and public listings, including Sanya Atlantis and commercial real estate REITs, which could enhance portfolio transparency and valuation recovery.
- The company's adjusted NAV per share reached HK$18.1, with a price-to-NAV ratio of 0.29, indicating a strong discount and potential for share price appreciation.
- Fosun International Ltd (FOSUF) is investing heavily in innovation and AI, with R&D expenditure up 16.7% year-on-year to RMB4.2 billion, and AI initiatives reducing R&D cycles from 18 months to 5 months in some cases.
- The company's core subsidiaries, including Fosun Pharma, Yuyuan, and Hainan Mining, delivered strong results, with Fosun Pharma's innovative drug sales accounting for 33% of total sales and Hainan Mining's net profit up 83% year-on-year.
Negative
- Fosun International Ltd (FOSUF) faces a challenging macro environment, with total revenue growth of only 3% year-on-year, and the happiness segment saw a slight revenue decline of 6.2% due to macroeconomic pressures.
- The company's adjusted NAV per share of HK$18.1 and price-to-NAV ratio of 0.29 indicate that the market still values the company at a significant discount, reflecting ongoing investor concerns.
- Fosun International Ltd (FOSUF) continues to carry a high level of debt, with group-level interest-bearing liabilities at RMB85.4 billion, and the company's mid-term target of RMB60 billion requires substantial asset divestments and cash generation.
- The company's asset management segment saw a slight revenue decrease due to the divestment of HRL, and the group is still in the process of disposing non-core assets, which may take time to complete.
- Fosun International Ltd (FOSUF) faces competitive pressures in the consumption industry, particularly in the jewelry and fashion sectors, where the company is working to improve gross margins and brand positioning.
- The company's overseas operations, while growing, are subject to geopolitical and economic uncertainties, and the management acknowledged that external uncertainty is intensifying, which could impact future performance.
- Fosun International Ltd (FOSUF) has a complex organizational structure with multiple business segments, which may lead to higher administrative expenses and operational inefficiencies, despite efforts to streamline.
- The company's reliance on asset divestments for cash flow and debt reduction may not be sustainable in the long term, and the pace of divestments could be affected by market conditions.
- Fosun International Ltd (FOSUF) faces risks related to its pharmaceutical pipeline, including the potential failure of key drugs like AR1001 for Alzheimer's disease, which could impact future revenue growth.
- The company's insurance businesses, while profitable, are subject to regulatory changes and market volatility, and the combined ratios of 92% and 91% for Fidelidade and Peak Re, respectively, indicate limited underwriting margins.
Tai Yiqin Fosun International Ltd;Co;Chief Financial Officer
Dear investors, analysts, partners, and friends from the media, good morning.
Today, we can strongly feel your attention to Fosa International. I would like to thank you all for being here, and I would like to thank the guests online.
I am co-CFO of Fosa International, Tai Yiqin. First, let me introduce. The leaders from Fosun International. First, we have Chairman of Fosun International, Mr. Pu Guangchang.
Co-Chairman of Fosun International, Mr. Wang Qingbing.
Executive Director, Co-CEO of Fosun International, Mr. Chen Xiyu.
Executive Director and Co-CEO of Fosun International, Mr. Xu Xiaoliang.
And Executive Director, Executive President and CFO of FOSE International, Mr. Gong Ping.
Today, we will have two sessions. In the morning session, FOSE International's management team will brief on the financials, business, and strategic development for the first half of 2026. In the afternoon session, the head of four business segments will share on the
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers